Last update Aug. 19, 2021
Very Low Risk
Long-acting beta-2 adrenergic agonist sympathomimetic with properties similar to salbutamol.
Indicated in the treatment of asthma.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its very wide volume of distribution (Boehringer 2020 and 2019) and the fact that, after inhalation, it reaches very low or undetectable plasma concentrations, (Wang 2020, Ichinose 2015) making it very unlikely that significant amounts will pass into breast milk.
Its almost zero absorption and oral bioavailability (Boehringer 2020 and 2019) makes it difficult for it to pass to the infant plasma from ingested breast milk.
Experts and scientific societies consider the use of inhaled adrenergic agonists to be low risk during breastfeeding (Lactmed, Amir 2011, National Asthma Education 2004).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.